Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INO-3107 With Electroporation in Recurrent Respiratory Papillomatosis
NCT04398433Phase 2Completed
- Sponsor
- Inovio Pharmaceuticals, Inc.
- Start
- Oct 2020
- Primary completion
- Dec 2022
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of doruxapapogene ralaplasmid in recurrent respiratory papillomatosis (RRP), sponsored by Inovio Pharmaceuticals, Inc.. Started Oct 2020; status: completed.
02
Drugs
doruxapapogene ralaplasmid
03
Conditions
recurrent respiratory papillomatosis (RRP)
Beyond the preview
Go deeper on NCT04398433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04398433.